Pages that link to "Q35166960"

The following pages link to A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors (Q35166960):

Displaying 26 items.

• TLR2, but not TLR4, is required for effective host defence against Chlamydia respiratory tract infection in early life. (Q34314450) (← links)
• Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses (Q36020045) (← links)
• Use of the Microparticle Nanoscale Silicon Dioxide as an Adjuvant To Boost Vaccine Immune Responses against Influenza Virus in Neonatal Mice. (Q36811968) (← links)
• Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant (Q37198471) (← links)
• Ag85A DNA Vaccine Delivery by Nanoparticles: Influence of the Formulation Characteristics on Immune Responses (Q37293872) (← links)
• Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants. (Q37352073) (← links)
• Assessment of the role in protection and pathogenesis of the Chlamydia muridarum V-type ATP synthase subunit A (AtpA) (TC0582). (Q37624678) (← links)
• A vaccine formulated with a combination of TLR-2 and TLR-9 adjuvants and the recombinant major outer membrane protein elicits a robust immune response and significant protection against a Chlamydia muridarum challenge (Q37662675) (← links)
• Update on Chlamydia trachomatis Vaccinology (Q37834874) (← links)
• Computational modeling of TC0583 as a putative component of the Chlamydia muridarum V-type ATP synthase complex and assessment of its protective capabilities as a vaccine antigen (Q37838165) (← links)
• Beyond "safe sex"--can we fight adolescent pelvic inflammatory disease? (Q37848511) (← links)
• The use of Toll-like receptor 7/8 agonists as vaccine adjuvants (Q38124064) (← links)
• An overview of adjuvant formulations and delivery systems. (Q38126953) (← links)
• Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists. (Q38992678) (← links)
• Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice (Q41539694) (← links)
• The yin and yang of human Beta-defensins in health and disease (Q42473672) (← links)
• Chlamydia abortus Pmp18.1 Induces IL-1β Secretion by TLR4 Activation through the MyD88, NF-κB, and Caspase-1 Signaling Pathways (Q47352451) (← links)
• Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics (Q47590580) (← links)
• Future of human Chlamydia vaccine: Potential of self-adjuvanting biodegradable nanoparticles as safe vaccine delivery vehicles (Q47643650) (← links)
• Streptococcus pneumoniae Attenuated Strain SPY1 with an Artificial Mineral Shell Induces Humoral and Th17 Cellular Immunity and Protects Mice against Pneumococcal Infection (Q48521617) (← links)
• Crosstalk of dynamic functional modules in lung development of rhesus macaques (Q50530547) (← links)
• Vaccination of koalas (Phascolarctos cinereus) against Chlamydia pecorum using synthetic peptides derived from the major outer membrane protein. (Q55472927) (← links)
• The M278 Major Outer Membrane Peptide Encapsulated in the Poly(lactic acid)-Poly(ethylene glycol) Nanoparticulate Self-Adjuvanting Delivery System Protects Mice Against a Genital Tract Challenge by Stimulating Robust Systemic and Local Mucosal Immune (Q58122056) (← links)
• Seventy Years of Vaccine Research - Limitations of the Past and Directions for the Future (Q61805093) (← links)
• TLR2 agonism reverses chemotherapy-induced neutropenia in Macaca fascicularis (Q89777663) (← links)
• Protection against a chlamydial respiratory challenge by a chimeric vaccine formulated with the Chlamydia muridarum major outer membrane protein variable domains using the Neisseria lactamica porin B as a scaffold (Q94923882) (← links)